Business Wire

Max Levy appointed Chief Investment Officer in newly created role

Lilly H. Donohue, a long-time senior living industry executive, to join Board of Directors

DALLAS--(BUSINESS WIRE)-- Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner-operator and investor in communities and services for seniors, today announced the appointment of Max Levy to the newly created role of Chief Investment Officer (“CIO”). In addition,... (continue reading...)

DAVIDSON, N.C.--(BUSINESS WIRE)-- Ingersoll Rand Inc. (NYSE: IR) (the “Company” or “Ingersoll Rand”), a global provider of mission-critical flow creation and industrial solutions, announced today that the Company has successfully completed a series of transactions issuing Senior Unsecured Bonds and putting in place a new Senior Unsecured Revolving Credit Facility.

The Company raised $3,276 million in net proceeds from the bond offering, of which $1,236... (continue reading...)

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024.

First Quarter 2024 Financial Results

Net Income (Loss) from Continuing Operations

• Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from... (continue reading...)

PEORIA, Ill.--(BUSINESS WIRE)-- RLI Corp. (NYSE: RLI) -- RLI Corp. announced today the promotion of Deb Millum to Vice President, Claim. In her new role, Millum will assume executive leadership and oversight responsibility for RLI’s Transportation, Non-Transportation Auto and Personal Umbrella product claims.

Millum joined RLI in 2017 as Director, Claim Counsel and was promoted to Assistant Vice President, Claim Counsel in 2019. She brings nearly 30 years of... (continue reading...)

• Engineering of X-Editors (XE), Scribe’s proprietary genome editing platform, for potency and specificity enables XE to become the first non-Cas9-based molecule to achieve saturating levels of editing in the NHP liver (exceeding 75% whole liver editing) without any detectable off-targets
• Data also highlight the ability of XE to achieve safe and saturated levels of editing in transduced photoreceptors in the mouse retina and rescue of visual response in a mouse... (continue reading...)